Furthermore, bioinformatics analysis and in vivo verification have suggested that GPSM2 negatively influenced patient response to paclitaxel, one of the most effective and well-tolerated chemotherapy drugs for breast cancer [10]. Here, GPSM2 is linked to breast cancer.